No tax

ZEFFIX PILLS 100MG - 28 tabs



Security policy (edit with Customer reassurance module)


Delivery policy (edit with Customer reassurance module)


Return policy (edit with Customer reassurance module)


Composition and release form

Zeffix - coated tablets:

1 tab. contains lamivudine 100 mg; 14, 28, or 84 pcs per pack;

Zeffix - solution for oral administration:

1 ml contains lamivudine 5 mg; in bottles of 240 ml, complete with a dosing syringe and adapter for the syringe, in a box 1 pc.

pharmachologic effect

Antiviral drug - nucleoside analogue. Zeffix is ​​highly active against the hepatitis B virus. In both infected and uninfected cells, lamivudine is metabolized to lamivudine triphosphate, which is the active form of the drug and serves as a substrate for the hepatitis B virus polymerase. further formation of viral DNA. Lamivudina triphosphate does not violate the normal cellular DNA metabolism. It is also a weak inhibitor of mammalian α- and β-DNA polymerases. Lamivudina triphosphate does not have a significant effect on the DNA content in cells.


Chronic hepatitis B against the backdrop of hepatitis B virus replication


Hypersensitivity to lamivudine or to any other component of Zeffix, pregnancy (I term).

Caution should be used for renal failure, pancreatitis (including history), peripheral neuropathy, pregnancy (II-III trimester), during lactation, in childhood (up to 2 years).

Side effects

The most common side effects are general malaise and fatigue, respiratory infections, headache, discomfort and abdominal pain, nausea, vomiting and diarrhea.

The frequency of changes in laboratory parameters in patients with chronic hepatitis B is similar when using Zeffix and placebo; the exception is more frequent increases in the level of ALT after completion of therapy with Zeffix. However, a significant difference in the frequency of elevated ALT levels, combined with an increase in bilirubin levels and / or signs of liver failure, is not detected. It is not known whether these cases of exacerbation of hepatitis are associated with treatment with Zeffix or with the course of chronic hepatitis itself.

In patients with HIV infection, cases of pancreatitis and peripheral neuropathy (or paresthesia) were observed, but the association of these complications with lamivudine therapy has not been proven.There was no significant difference in the incidence of these complications in the groups of patients with chronic hepatitis B who took Zeffix and placebo.

In patients with HIV infection who received combination therapy with nucleoside analogues, there were cases of lactic acidosis, which was usually accompanied by severe hepatomegaly and fatty liver dystrophy. There are separate reports of the same side effects in patients with viral hepatitis B and liver failure; however, there is no data confirming the connection of these complications with Zeffix.

Dosage and administration

Zeffiks take orally, regardless of the meal.

Adults and children aged 12 years and older: 100 mg 1 time per day.

Children from 2 to 11 years: 3 mg / kg 1 time per day, but not more than 100 mg / day.

Children under 2 years: not enough data to recommend dosages in this age group.

special instructions

Zeffix in the form of an oral solution is used to treat children and those patients who cannot take the drug in the form of tablets.

During treatment with Zeffix, the patient’s condition should be regularly monitored by a physician experienced in the treatment of chronic hepatitis B.

Storage conditions and shelf life

The drug should be stored in a dry, dark place at temperatures not above 20 ° C. Shelf life - 3 years.

49 Items